Australia Genomics Market Size, Trends, Demand and Outlook 2025-2033

The latest report by IMARC Group, “Australia Genomics Market Size, Share, Trends, and Forecast by Component, Application, Technology, End-User, and Region, 2025-2033,” provides an in-depth analysis of the Australia genomics market. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry. The Australia genomics market size reached USD 1.08 billion in 2024 and is projected to grow to USD 3.92 billion by 2033, exhibiting a CAGR of 13.80% during 2025-2033.

Report Attributes and Key Statistics:

Australia Genomics Market Overview:

The Australia genomics market is growing quickly as healthcare providers, research institutions, and government organizations incorporate genomics into regular medical practice. Stakeholders are investing in new sequencing technologies and AI-driven data analysis. Meanwhile, the government is supporting national genomics programs and improving infrastructure. Efforts are underway to extend genomic services to regional and remote communities to ensure fair access. These initiatives are driving innovation, improving diagnostic accuracy, and helping develop personalized medicine, ultimately changing the healthcare landscape in Australia.

Request For Sample Report: https://www.imarcgroup.com/australia-genomics-market/requestsample

Australia Genomics Market Trends and Drivers:

The market is seeing a rise in the use of AI-powered genomics platforms. These platforms speed up the analysis of complex genetic data and support precision medicine. Partnerships between research centers and clinical providers are translating research into clinical applications. The government’s investment in AI and genomics is aiding the integration of genomic testing into everyday healthcare. At the same time, the growth of next-generation sequencing (NGS) technologies is making high-throughput, cost-effective testing more accessible. These trends are positioning Australia as a leader in genomic innovation and healthcare change.

Key drivers include the rising demand for personalized and precision medicine, significant government funding for genomics research and infrastructure, and improvements in sequencing and data analysis technologies. Better public awareness of the benefits of genetic testing, along with national efforts to include genomics in standard care, are boosting market growth. Collaboration among federal and state health systems, research groups, and clinical providers is also improving access to and relevance of genomics throughout Australia.

Market Challenges and Opportunities:

However, Australia’s genomics sector faces several challenges. There is a shortage of skilled workers in bioinformatics, clinical genetics, and genetic counseling. This talent gap slows the spread of genomic medicine in healthcare systems. Technological challenges remain, including disconnected data storage systems, high infrastructure costs, and problems interpreting large genomic datasets. Regulatory uncertainty, reimbursement issues, and changing clinical guidelines add more hurdles. Public concerns about data privacy and genetic discrimination also affect participation in genomic testing programs, harming both research efforts and clinical applications.

The Australian genomics market is benefiting from strong government support, especially through funding programs like the Genomics Health Futures Mission and Medicare rebates for clinical sequencing. The demand for personalized medicine, particularly in cancer care and rare diseases, is increasing. Advances in artificial intelligence and bioinformatics are improving genomic analysis and speeding up diagnostics. Regional and rural areas are achieving better access to genomic testing through telehealth solutions. Additionally, public-private partnerships, indigenous genomics projects, and rising awareness of genetic conditions are broadening the market’s reach and inclusivity across the country.

Australia Genomics Key Growth Drivers:

• Rising demand for personalized medicine

• Government investment in national genomics programs

• Advancements in sequencing and AI-driven technologies

• Increased awareness and acceptance of genetic testing

• Collaboration between research institutions and healthcare providers

Key Highlights of the Report:

• Comprehensive market size and forecast, 2024-2033

• Detailed segmentation by component, application, technology, end-user, and region

• In-depth analysis of technological trends and government initiatives

• Competitive landscape profiling major players and strategies

• Insights into the integration of genomics in routine healthcare

• Evaluation of regulatory, ethical, and data privacy considerations

Australia Genomics Market Segmentation:

• Component Insights:

  • Products

    • Instruments and Software

    • Consumables and Reagents

  • Services

    • Core Genomics Services

    • NGS-Based Services

    • Biomarker Translation Services

    • Computational Services

    • Others

• Application Insights:

  • Functional Genomics

  • Epigenomics

  • Biomarkers Discovery

  • Pathway Analysis

  • Others

• Technology Insights:

  • Sequencing

  • Microarray

  • Polymerase Chain Reaction

  • Nucleic Acid Extraction and Purification

  • Others

• End-User Insights:

  • Research Centers

  • Hospitals and Clinics

  • Pharmaceutical and Biotechnology Companies

  • Others

• Regional Insights:

  • Australia Capital Territory & New South Wales

  • Victoria & Tasmania

  • Queensland

  • Northern Territory & Southern Australia

  • Western Australia

Competitive Landscape:

• Illumina Inc.

• Thermo Fisher Scientific Inc.

• Agilent Technologies Inc.

• Roche Holding AG

• Qiagen NV

• Bio-Rad Laboratories Inc.

• Danaher Corp

• Eppendorf

• Eurofins Scientific SE

• Myriad Genetics Inc.

• Oxford Nanopore Technologies PLC

• Pacific Biosciences of California Inc.

• Quest Diagnostics Inc.

• 23andMe Holding Co Class A

Australia Genomics Market News:

1. Launch of Genomics Australia (July 2025)

• The federal government officially launched Genomics Australia, a national body embedded within the Department of Health and Ageing. Its mandate includes integrating genomic research into clinical care across the country.

• Tiffany Boughtwood has been appointed as Australia’s first Health Genomics Commissioner, tasked with guiding the rollout of this initiative and steering national genomics policy.

• In tandem, the Medical Research Future Fund (MRFF) has allocated $50 million across 30 genomics-focused projects, supporting early detection and personalized medicine, including for children with Type 1 diabetes, cancer risk groups, and First Nations populations.

2. Polygenic Risk Scores (PRS) Gain Momentum

• The Genomics Australia launch coincided with a surge in interest around polygenic risk scores (PRS)—genetic assessments that estimate an individual's likelihood of developing conditions like cancer, heart disease, or glaucoma.

• A widely circulated example: a nurse used a PRS test and discovered a moderate colorectal cancer risk, prompting heightened medical oversight.

• While only 11% of Australians were aware of PRS as of early 2025, around 75% expressed willingness to consider testing after learning about it. Companies like Rhythm Biosciences and Seonix Bio are already offering PRS-based tests, which may soon be integrated into routine care.

Note: If you require specific information not currently within the scope of the report, we can provide it as part of the customization.

Ask an analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=34072&flag=C

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel. No.: (D) +91 120 433 0800
Americas: +1-201-971-6302